Thursday 16 October, 2025
Objectives: Our goal was to develop a mechanistic mathematical model capable of predicting neutralization of soluble monomeric Aβ in the…
Read morePoster: Drug/Disease modeling - CNS
Mechanistic model of amyloid beta (Aß) and anti-Aß mAb dynamics
Thursday 16 October, 2025
Objectives: Our goal was to develop a mechanistic mathematical model capable of predicting neutralization of multiple Aβ species in the…
Read moreAnalysis of Sleep Changes Induced by Citalopram: A Population Approach
Thursday 16 October, 2025
Objectives: To develop a population kinetic-pharmacodynamic (KPD) model that describes the pattern of sleep and quantifies the sleep changes in…
Read moreQuantification of the effect of AZD5213 on sleep in subjects with Alzheimer’s disease or mild cognitive impairment using a two state Markov model
Thursday 16 October, 2025
Objectives: H3 antagonists have been extensively investigated for the (symptomatic) treatment of cognitive disorders, such as Alzheimer’s disease (AD) or mild…
Read moreA population pharmacokinetic model for aripiprazole and dehydro-aripiprazole
Thursday 16 October, 2025
Objectives: The aim of this work was to develop a population pharmacokinetic (PK) model for aripiprazole and its metabolite, dehydro-aripiprazole. …
Read moreClinical trial simulation and hypothesis testing using amyloid pathology longitudinal translational model
Thursday 16 October, 2025
Objectives: Amyloid (Ab) is one of the main targets in Alzheimer’s disease (AD) therapy. The goal of this work was to…
Read moreModelling and Simulation of Motor Symptom Measurements in Parkinson’s Disease after L-Dopa Administration
Thursday 16 October, 2025
Objectives: To simultaneously characterize multiple motor symptom measurements such as Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale Part 3…
Read morePopulation pharmacokinetic model of delta-9-tetrahydrocannabinol (THC) in cannabis occasional smokers
Thursday 16 October, 2025
Objectives: Cannabis is the most widely used illegal drug in the world. Delta-9-tetrahydrocannabinol (THC) is the main source of the pharmacological…
Read moreDevelopment of a mechanism-based pharmacokinetic-pharmacodynamic model of prolactin response following administration of D2 antagonists in rats
Thursday 16 October, 2025
Objectives:Schizophrenia is characterized by dopamine dysregulation. Treatment with D2 antagonists results in side effects including prolactin release, which manifests clinically…
Read moreIntegrating tracer kinetic data with absolute protein concentration measurements in a systems pharmacology model. Application to the APP pathway in CMP rhesus monkeys.
Thursday 16 October, 2025
Objectives: Integrating biomarkers from different analytical tools to gain understanding of the underlying biological system in a comprehensive model can…
Read more